Wensheng Yu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/468462/publications.pdf

Version: 2024-02-01

40 papers	641 citations	516710 16 h-index	642732 23 g-index
40 all docs	40 docs citations	40 times ranked	674 citing authors

#	Article	IF	Citations
1	Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 389-396.	2.8	14
2	Mild Condition for the Deoxygenation of Î±-Heteroaryl-Substituted Methanol Derivatives. Journal of Organic Chemistry, 2021, 86, 5560-5567.	3.2	3
3	Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity. Journal of Medicinal Chemistry, 2021, 64, 4709-4729.	6.4	7
4	Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128168.	2.2	6
5	SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128214.	2.2	4
6	Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128314.	2.2	7
7	In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform. SLAS Discovery, 2021, 26, 642-654.	2.7	3
8	Scalable Preparation of 4,4-Disubstituted Six-Membered CyclicÂSulfones. Organic Letters, 2021, 23, 943-947.	4.6	8
9	Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group. ACS Medicinal Chemistry Letters, 2020, 11, 2476-2483.	2.8	27
10	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1548-1554.	2.8	44
11	Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127390.	2.2	16
12	Selective N7 Alkylation of 7-Azaindazoles. Journal of Organic Chemistry, 2020, 85, 7558-7564.	3.2	3
13	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance. ACS Medicinal Chemistry Letters, 2020, 11, 1476-1483.	2.8	21
14	Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). ACS Medicinal Chemistry Letters, 2020, 11, 550-557.	2.8	28
15	Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127367.	2.2	14
16	Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127197.	2.2	19
17	Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2019, 10, 1530-1536.	2.8	38
18	Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 700-706.	2.2	4

#	Article	IF	Citations
19	Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions. Journal of Medicinal Chemistry, 2018, 61, 3984-4003.	6.4	12
20	MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1954-1957.	2.2	5
21	In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	2
22	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3037-3042.	2.2	8
23	Development of a prodrug of hydantoin based TACE inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3704-3708.	2.2	5
24	Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. Journal of Medicinal Chemistry, 2017, 60, 290-306.	6.4	42
25	Discovery of novel BTK inhibitors with carboxylic acids. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1471-1477.	2.2	17
26	Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4106-4111.	2.2	15
27	Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3158-3162.	2.2	17
28	Discovery of potent macrocyclic HCV NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3793-3799.	2.2	10
29	Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3800-3805.	2.2	17
30	Structureâ€“activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5354-5360.	2.2	12
31	Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5132-5137.	2.2	13
32	Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4851-4856.	2.2	13
33	Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2016, 59, 10228-10243.	6.4	26
34	Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3414-3420.	2.2	15
35	A high-yielding method for the preparation of isoxazolopyridin-3-amine derivatives. Green Chemistry, 2016, 18, 4941-4946.	9.0	8
36	Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1475-1479.	2.2	21

#	Article	IF	Citations
37	Discovery and SAR of hydantoin TACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1877-1880.	2.2	48
38	The discovery of novel tartrate-based TNF-Î± converting enzyme (TACE) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1189-1193.	2.2	26
39	Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5286-5289.	2.2	23
40	Novel TNF-Î± converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7283-7287.	2.2	20